ANN ARBOR, Mich.–(BUSINESS WIRE)–Millendo
Therapeutics, Inc., a clinical-stage biopharmaceutical company
focused on developing novel treatments for orphan endocrine diseases,
today announced that Julia C. Owens, Ph.D., President and Chief
Executive Officer, will participate in the following August conferences:
2018 Oppenheimer Newport Summit for Revolutionary Biotechnology on
Monday, August 13, 2018 in Newport, RI, where the Company will host
2018 Wedbush PacGrow Healthcare Conference, where the Company will
provide a corporate overview and pipeline update on Wednesday, August
15, 2018 at 9:45 AM ET in New York, NY
About Millendo Therapeutics, Inc.
Millendo Therapeutics is
focused on developing novel treatments for orphan endocrine diseases.
The Company’s objective is to build a leading endocrine company that
creates distinct and transformative treatments for a wide range of
diseases where there is a significant unmet medical need. The Company is
currently advancing livoletide for the treatment of Prader-Willi
syndrome and nevanimibe for the treatment of classic congenital adrenal
hyperplasia and endogenous Cushing’s syndrome. For more information,
please visit www.millendo.com.